del ZoppoGJPoeckKPessinMS. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol1992); 32: 78–86.
2.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med1995); 333: 1581–7.
3.
KwiatkowskiTGLibmanRBFrankelM. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National institute of neurological disorders and stroke recombinant tissue plasminogen activator stroke study group. N Engl J Med1999); 340: 1781–7.
4.
FaganSCMorgensternLBPetittaA. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA stroke study group. Neurology1998); 50: 883–90.
5.
HillMDBuchanAM: Canadian alteplase for stroke effectiveness study (CASES) investigators. Thrombolysis for acute ischemic stroke: Results of the Canadian alteplase for stroke effectiveness study. CMAJ2005); 172: 1307–12.
HackeWDonnanGFieschiC. ATLANTIS trials investigators; ECASS trials investigators; NINDS rt-PA study group investigators. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet2004); 363: 768–74.
FurlanAHigashidaRWechslerL. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA1999); 282: 2003–11.
11.
IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The interventional management of stroke study. Stroke2004); 35: 904–11.
12.
BroderickJP: Interventional Management of Stroke Trial III (WWW Document). IMS3 2006; URL http://ims3.org/. (Accessed May 8, 2006).